Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma

NYU Clinical Cancer Center, New York

New York Medical College, Valhalla

Interlakes Foundation, Rochester

Allegheny-Singer Research Institute, Pittsburgh

Western Pennsylvania Cancer Institute, Pittsburgh

Temple University, Philadelphia

Marshall University, Huntington

West Virginia University Health Science Center, Morgantown

Northwest Georgia Oncology Centers, PC, Marietta

Ocala Cancer Institute, Ocala

Northwest Alabama Center, PC, Muscle Shoals

University of Tennessee Medical Center, Knoxville

Jackson Oncology Associates, PLLC, Jackson

Purchase Cancer Group, Paducah

Gabrail Cancer Center, Canton

Cancer Care Center, Inc., New Albany

St. Joseph Mercy Hospital, Ann Arbor

Kalamazoo Hematology and Oncology, Kalamazoo

Siouxland Hematology Oncology Associates, Sioux City

Marshfield Clinic, Marshfield

Avera Cancer Institute, Sioux Falls

Alexian Brothers Hospital Network, Elk Grove Village

Clintell, Inc., Skokie

Southern Illinois Hematology Oncology, Centralia

St. Louis Cancer Care, LLP, Chesterfield

Hutchinson Clinic, Hutchinson

Nebraska Hematology-Oncology, PC, Lincoln

Great Plains Regional Medical Center, North Platte

Medical Oncology, LLC, Baton Rouge

Oklahoma Oncology and Hematology, PC, Oklahoma City

Oklahoma Oncology and Hematology, PC, Tulsa

HOPE Oncology, Richardson

Northern Utah Associates, Ogden

San Juan Oncology Associates, Farmington

Southern Nevada Cancer Research Foundation, Las Vegas

Providence Saint Joseph Medical Center, Burbank

Desert Hematology Medical Group, Inc., Rancho Mirage

Loma Linda U Cancer Center, Loma Linda

Pacific Coast Hematology Oncology Medical Group, Fountain Valley

Cancer Center of Central Connecticut, Southington

Dartmouth Hitchcock Medical Center, Lebanon

Landmark Medical Center, Woonsocket

Auxilio Cancer Center, Hato Rey